MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential
Standard
MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. / Matuszcak, Christiane; Haier, Joerg; Hummel, Richard; Lindner, Kirsten.
In: WORLD J GASTROENTERO, Vol. 20, No. 38, 14.10.2014, p. 13658-66.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential
AU - Matuszcak, Christiane
AU - Haier, Joerg
AU - Hummel, Richard
AU - Lindner, Kirsten
PY - 2014/10/14
Y1 - 2014/10/14
N2 - Gastric cancer (GC) is the fourth most common cancer worldwide and ranks second in global cancer mortality statistics. Perioperative chemotherapy plays an important role in the management and treatment of advanced stage disease. However, response to chemotherapy varies widely, with some patients presenting no or only minor response to treatment. Hence, chemotherapy resistance is a major clinical problem that impacts on outcome. Unfortunately, to date there are no reliable biomarkers available that predict response to chemotherapy before the start of the treatment, or that allow modification of chemotherapy resistance. MicroRNAs (miRNAs) could provide an answer to this problem. miRNAs are involved in the initiation and progression of a variety of cancer types, and there is evidence that miRNAs impact on resistance towards chemotherapeutic drugs as well. This current review aims to provide an overview about the potential clinical applicability of miRNAs as biomarkers for chemoresistance in GC. The authors focus in this context on the potential of miRNAs to predict sensitivity towards different chemotherapeutics, and on the potential of miRNAs to modulate sensitivity and resistance towards chemotherapy in GC.
AB - Gastric cancer (GC) is the fourth most common cancer worldwide and ranks second in global cancer mortality statistics. Perioperative chemotherapy plays an important role in the management and treatment of advanced stage disease. However, response to chemotherapy varies widely, with some patients presenting no or only minor response to treatment. Hence, chemotherapy resistance is a major clinical problem that impacts on outcome. Unfortunately, to date there are no reliable biomarkers available that predict response to chemotherapy before the start of the treatment, or that allow modification of chemotherapy resistance. MicroRNAs (miRNAs) could provide an answer to this problem. miRNAs are involved in the initiation and progression of a variety of cancer types, and there is evidence that miRNAs impact on resistance towards chemotherapeutic drugs as well. This current review aims to provide an overview about the potential clinical applicability of miRNAs as biomarkers for chemoresistance in GC. The authors focus in this context on the potential of miRNAs to predict sensitivity towards different chemotherapeutics, and on the potential of miRNAs to modulate sensitivity and resistance towards chemotherapy in GC.
KW - Animals
KW - Antineoplastic Agents
KW - Biomarkers, Tumor
KW - Drug Resistance, Neoplasm
KW - Gene Expression Regulation, Neoplastic
KW - Genetic Testing
KW - Genetic Therapy
KW - Humans
KW - MicroRNAs
KW - Patient Selection
KW - Precision Medicine
KW - Predictive Value of Tests
KW - Stomach Neoplasms
KW - Treatment Outcome
U2 - 10.3748/wjg.v20.i38.13658
DO - 10.3748/wjg.v20.i38.13658
M3 - SCORING: Journal article
C2 - 25320504
VL - 20
SP - 13658
EP - 13666
JO - WORLD J GASTROENTERO
JF - WORLD J GASTROENTERO
SN - 1007-9327
IS - 38
ER -
